We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CryoPort, Inc. (CYRX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CryoPort, Inc. is a member of the Medical sector. This group includes 917 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CryoPort, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CYRX's full-year earnings has moved 2.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, CYRX has returned 81.3% so far this year. Meanwhile, the Medical sector has returned an average of 1.6% on a year-to-date basis. This shows that CryoPort, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Delcath Systems, Inc. (DCTH - Free Report) . The stock is up 58.1% year-to-date.
For Delcath Systems, Inc., the consensus EPS estimate for the current year has increased 80.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, CryoPort, Inc. is a member of the Medical Services industry, which includes 70 individual companies and currently sits at #106 in the Zacks Industry Rank. On average, stocks in this group have gained 3.1% this year, meaning that CYRX is performing better in terms of year-to-date returns.
In contrast, Delcath Systems, Inc. falls under the Medical - Instruments industry. Currently, this industry has 78 stocks and is ranked #85. Since the beginning of the year, the industry has moved -4.8%.
CryoPort, Inc. and Delcath Systems, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CryoPort, Inc. (CYRX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CryoPort, Inc. is a member of the Medical sector. This group includes 917 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CryoPort, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CYRX's full-year earnings has moved 2.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, CYRX has returned 81.3% so far this year. Meanwhile, the Medical sector has returned an average of 1.6% on a year-to-date basis. This shows that CryoPort, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Delcath Systems, Inc. (DCTH - Free Report) . The stock is up 58.1% year-to-date.
For Delcath Systems, Inc., the consensus EPS estimate for the current year has increased 80.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, CryoPort, Inc. is a member of the Medical Services industry, which includes 70 individual companies and currently sits at #106 in the Zacks Industry Rank. On average, stocks in this group have gained 3.1% this year, meaning that CYRX is performing better in terms of year-to-date returns.
In contrast, Delcath Systems, Inc. falls under the Medical - Instruments industry. Currently, this industry has 78 stocks and is ranked #85. Since the beginning of the year, the industry has moved -4.8%.
CryoPort, Inc. and Delcath Systems, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.